Other considered targets include gastrin releasing peptide receptor (GRPr) with bombesin (169) or GRPr-antagonist RM26 (170), αVβ3 integrin (169), NK1 receptors, with Substance P (171), HCC with SP94 peptide (172), VEGFR (173) or GRP78, a specific cancer cell-surface marker (174). This evidence concerns the gene GRPR and cancer.